Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Anti-Cancer Medicines Availability Study

AntiNeoplastics Medicines Availability study banner

ESMO working to improve the availability of anti-cancer medicines in in Europe and worldwide

The availability of cancer medicines is crucial for medical oncologists to be able to treat patients according to the evidence-based ESMO Clinical Practice Guidelines.

As a follow-up to the ESMO studies on the availability of opioids for cancer pain management, ESMO conducted a European and international study on the availability of anti-neoplastic medicines based on feedback from ESMO members and oncology pharmacists.

Read the ESMO European and International study publications by clicking on the links in the boxes below.

Study objectives

  • To provide health authorities with data on the availability of licensed anti-neoplastic medicines
  • To report on the actual availability of anti-neoplastic medicines to patients when they are prescribed and when patients can afford them
  • To provide data so that policy makers can decide how to best address and resolve the challenges identified

Study results

The ESMO studies showed that internationally there is a growing disparity between licensed anti-cancer medicines and those that are actually available, leading to medicines shortages.

Data from the ESMO studies was valuable to the  World Health Organization, who cited the studies as the most comprehensive assessment on the availability of cancer medicines globally in the 2018 WHO Technical Report on the pricing of cancer medicines and its impacts.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings